Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty

https://doi.org/10.1016/S0002-9149(00)01368-0Get rights and content

Section snippets

Acknowledgements

We authors are grateful for the cooperation of the Rambam Coronary Catheterization Laboratory and Cardiology Department.

First page preview

First page preview
Click to open first page preview

References (15)

There are more references available in the full text version of this article.

Cited by (48)

  • Haptoglobin 2 allele associates with unstable carotid plaque and major cardiovascular events

    2013, Atherosclerosis
    Citation Excerpt :

    If it will turn out that different Hp genotypes do indeed associate with distinct stroke subtypes, ultimately the determination of Hp genotypes might assist in stroke risk stratification and individualized pharmacogenomics. Hp2-2 genotype has previously been associated with the severity of myocardial infarction [22] and vascular complications in diabetics, including retinopathy, nephropathy, cardiovascular morbidity and restenosis after coronary intervention [14–18]. However, hp2 allele has not previously been associated with cardiovascular morbidity in the general population.

  • Haptoglobin gene polymorphism in type 2 diabetic patients with and without nephropathy: An Egyptian study

    2007, European Journal of Internal Medicine
    Citation Excerpt :

    The increased antioxidant function of Hp 1-1 is thought to confer protection from angiopathies; however, Hp 2-2 is believed to be a major risk factor in several oxidative stress-related disease states [9]. This has been reported for coronary [10] and peripheral [11] atherosclerotic lesions, cardiac transplant vasculopathy [12], mortality in coronary heart disease [13], restenosis after coronary angioplasty [14]or stenting [15], and cardiovascular disease in diabetic individuals [16]. Also, the Hp phenotype is an apparent risk factor for the development of gestational diabetes mellitus [17].

  • The Pathophysiology and Burden of Restenosis

    2007, American Journal of Cardiology
View all citing articles on Scopus

This study was supported by grants from the Israel Cancer Association, Givatayim, Israel; Israel Cancer Research Fund, New York, New York; Israel Science Foundation, Jerusalem, Israel; Rappaport Fund for Research, Haifa, Israel; and the National Institutes of Health (NIHR01), Bethesda, Maryland.

View full text